Eyenovia Announces Pricing of $5.14 Million Public Offering

Core Viewpoint - Eyenovia, Inc. has announced an agreement to sell 12,850,000 shares of common stock at a price of $0.40 per share, aiming to raise approximately $5.14 million in gross proceeds to fund various activities including commercialization and clinical studies [1][2]. Group 1: Offering Details - The closing of the Offering is expected around August 22, 2024, pending customary closing conditions [2] - Dawson James Securities, Inc. is acting as the placement agent for the Offering [2] - The net proceeds will be used for commercialization activities for Mydcombi and clobetasol propionate, completing the CHAPERONE pediatric myopia clinical study, and for working capital, including potential debt repayment [2] Group 2: Company Overview - Eyenovia, Inc. specializes in ophthalmic technology, commercializing Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension, and developing the Optejet® device for pediatric progressive myopia [5]